Gilead (GILD) announced that the European Medicines Agency has validated for parallel accelerated review the company’s marketing authorization ...

Patients should have faster access to newly developed drugs and medicines and the Government is prepared to adopt new ...

KOMET-001 registrational trial in R/R NPM1-mutant AML achieved primary endpoint –– Alignment reached with FDA and EMA on key aspects of the ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Medicines Agency (EMA) has validated for parallel accelerated review the company’s ...

Foster City, California Tuesday, February 25, 2025, 16:00 Hrs [IST] ...

Gilead Sciences, Inc. has received conditional marketing authorization from the European Commission (EC) for Seladelpar for the treatment of primary biliary cholangitis (PBC) ...

Gilead Sciences (GILD) said on Friday that the European Commission (EC) granted conditional marketing authorization for ...

Biliary tract cancer is increasing in incidence and mortality across Europe, with more people under the age of 60 years old ...

Approved, Seladelpar Can Provide an Important Treatment Option for People Living With the Rare Liver Disease in the European Economic Area – ...

MUNICH, Germany, and BASILDON, UK I February 13, 2025 I LINDIS Biotech GmbH, a clinical stage biopharmaceutical company with a proprietary multi-specific ...

After steel and aluminum, U.S. President Donald Trump's next target in line of tariffs of as much as 25% are semiconductors, ...

After steel and aluminum, US President Donald Trump has set his sights on slapping 25 percent tariffs on semiconductors, cars ...